Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gonadal and Placental Hormones01:24

Gonadal and Placental Hormones

2.7K
The gonads, namely the testes in males and the ovaries in females, are pivotal in producing gonadal hormones that orchestrate the intricate processes of sexual development and reproduction.
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair...
2.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

433
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
433
Infertility in Males01:23

Infertility in Males

522
Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
522
Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

2.0K
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
2.0K
Hypothalamic-Pituitary Axis01:37

Hypothalamic-Pituitary Axis

65.4K
The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
65.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

452
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
452

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low Serum Testosterone Concentrations Predict Incident Frailty in Men with HIV.

The Journal of clinical endocrinology and metabolism·2026
Same author

Testosterone and Bone Health in Men.

Current osteoporosis reports·2026
Same author

Impact of Pre-treatment Testosterone Levels on Severity of Adverse Effects in Men on Androgen Deprivation Therapy for Prostate Cancer.

Andrology·2026
Same author

An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial.

JAMA·2025
Same author

BIO25-026: Innovating a Digital Patient Navigation Platform (DPNP) to Help Patients With Melanoma Access Multidisciplinary Cutaneous Oncology Care.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

Opioid-induced androgen deficiency in men: Prevalence, pathophysiology, and efficacy of testosterone therapy.

Andrology·2025

Related Experiment Video

Updated: Jan 13, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.4K

Emerging drugs for hypogonadism.

Daniel Edelstein1, Adrian Dobs, Shehzad Basaria

  • 1Johns Hopkins University School of Medicine, Division of Endocrinology and Metabolism, Baltimore, MD, USA.

Expert Opinion on Emerging Drugs
|October 27, 2006
PubMed
Summary

Testosterone therapy is increasingly used for male hypogonadism, with newer treatments offering better results. Future therapies like SARMs aim for targeted effects with fewer side effects.

Area of Science:

  • Endocrinology
  • Men's Health

Background:

  • Male hypogonadism is a prevalent endocrine condition affecting men across age groups.
  • There's a notable rise in testosterone use, including for borderline or normal levels in aging men.
  • Advancements in male hypogonadism treatments have occurred over recent decades.

Purpose of the Study:

  • To review current and emerging treatments for male hypogonadism.
  • To highlight the shift towards more advanced testosterone therapies.
  • To introduce novel compounds under development for androgen receptor modulation.

Main Methods:

  • Review of current testosterone replacement therapies.
  • Analysis of market trends in testosterone formulations.
  • Overview of investigational compounds for hypogonadism.

More Related Videos

Gonadectomy and Blood Sampling Procedures in the Small Size Teleost Model Japanese Medaka Oryzias latipes
05:31

Gonadectomy and Blood Sampling Procedures in the Small Size Teleost Model Japanese Medaka Oryzias latipes

Published on: December 11, 2020

4.9K
In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

8.0K

Related Experiment Videos

Last Updated: Jan 13, 2026

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.4K
Gonadectomy and Blood Sampling Procedures in the Small Size Teleost Model Japanese Medaka Oryzias latipes
05:31

Gonadectomy and Blood Sampling Procedures in the Small Size Teleost Model Japanese Medaka Oryzias latipes

Published on: December 11, 2020

4.9K
In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

8.0K

Main Results:

  • Transdermal and long-acting injectable testosterone undecanoate are replacing older esters.
  • A market shift favors more expensive, yet more physiological, transdermal therapies.
  • New compounds like SARMs, aromatase inhibitors, and others are in development.

Conclusions:

  • Modern testosterone therapies offer improved administration and physiological profiles.
  • Emerging treatments, including SARMs, promise targeted androgenic effects with potentially reduced side effects.
  • The landscape of male hypogonadism treatment is evolving towards more sophisticated and selective options.